Wuhan Qirui Pharmaceutical Co., Ltd. (a member company of the Qirui Group) was established in 2005 and is located in the Miaoshan Industrial Park in Jiangxia District, where it undertakes the Group’s two core businesses: formulation R&D and formulation manufacturing.

The company’s formulation R&D division focuses on four major therapeutic areas—autoimmune diseases, nephrology, respiratory diseases, and cardiovascular diseases—and has established an integrated small-molecule drug R&D platform that covers the entire drug development lifecycle, from CMC and pilot-scale manufacturing through clinical trials and regulatory registration to commercial production. Currently, the company has more than 20 projects in development, nine of which have already entered the clinical trial stage.

The formulation manufacturing segment focuses on the production of clinically essential drugs with proprietary intellectual property rights, including those for liver diseases, cardiovascular conditions, the digestive system, and antifungal indications; all marketed products are manufactured at scale by Qirui Pharmaceutical.

Qirui Pharmaceutical continuously enhances its core R&D capabilities and steadily advances the development of an intelligent manufacturing system, striving to elevate the automation, digitalization, and intelligence of its production processes and to build a modern drug R&D and manufacturing base that is more efficient, precise, and reliable.